危重症期间增加肠内蛋白质:TARGET Protein随机临床试验
该集群随机、交叉、开放标签试验在澳大利亚和新西兰的8个重症监护病房(ICU)纳入3397例接受肠内营养的危重症患者,比较增加蛋白质配方(100 g/L)与常规蛋白质配方(63 g/L)对90天内无索引医院住院且存活天数的影响。结果显示两组主要结局无显著差异,增加肠内蛋白质未改善该结局。
要点
- 增加肠内蛋白质组与常规蛋白质组90天内无索引医院住院且存活的中位天数分别为62天和64天,校正后中位差-1.97天(95%CI -7.24至3.30;P=0.46)。
- 第90天存活率:增加蛋白质组72.6%(1221/1681) vs 常规蛋白质组74.0%(1269/1716),风险比0.99(95%CI 0.95-1.03)。
- 次要结局包括存活者无医院住院天数、有创通气时长、ICU和住院时长、气管造口及新发肾脏替代治疗风险等,组间差异均未达统计学显著。
核心结论
- 危重症期间增加肠内蛋白质未改善90天内无索引医院住院且存活的天数。
研究设计与样本
- 集群随机、交叉、开放标签试验,于2022年5月23日至2023年8月23日在澳大利亚和新西兰的8个ICU招募接受肠内营养的危重症患者,最终随访日期为2023年11月21日。
- 共纳入3397例患者,中位年龄61岁(IQR 48-71),男性2157例(64%)。
- 比较两种等热量肠内配方:增加蛋白质(100 g蛋白质/L) vs 常规蛋白质(63 g蛋白质/L);各ICU在12个月内序贯使用配方3个月,4个ICU起始使用增加蛋白质配方,4个起始使用常规蛋白质配方。
主要发现
- 主要结局(90天内无索引医院住院且存活的中位天数):增加蛋白质组62天(IQR 0-77) vs 常规蛋白质组64天(IQR 0-77),校正周期后组间中位差-1.97天(95%CI -7.24至3.30;P=0.46)。
- 第90天存活:增加蛋白质组1221/1681例(72.6%) vs 常规蛋白质组1269/1716例(74.0%),风险比0.99(95%CI 0.95-1.03)。
- 存活者90天内无索引医院住院中位天数差0.01天(95%CI -1.94至1.96);有创通气平均时长差6.8小时(95%CI -3.0至16.5)。
- ICU住院时长(至活体转出ICU时间)病因特异性风险比0.93(95%CI 0.88-1.00),住院时长(至活体出院时间)病因特异性风险比0.96(95%CI 0.90-1.02);气管造口风险比1.15(95%CI 0.66-2.01),新发肾脏替代治疗风险比0.97(95%CI 0.81-1.16)。
- 出院去向两组相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Guidelines recommend augmenting enteral protein during critical illness, but the impact on patient outcomes is uncertain. OBJECTIVE: To determine whether augmenting enteral protein increases days alive and free from hospitalization. DESIGN, SETTING, AND PARTICIPANTS: This cluster randomized, crossover, open-label trial recruited critically ill patients receiving enteral nutrition from 8 intensive care units (ICUs) in Australia and New Zealand from May 23, 2022, to August 23, 2023, with final follow-up on November 21, 2023. INTERVENTION: Two isocaloric enteral formulae were compared: augmented protein (100 g protein/L) vs usual protein (63 g protein/L). ICUs used formulae sequentially for 3 months over a 12-month period; 4 ICUs commenced with augmented protein and 4 commenced with usual protein. MAIN OUTCOMES AND MEASURES: The primary outcome was the number of days free of admittance to the index hospital and alive at day 90. Secondary outcomes included days free of the index hospital at day 90 in survivors; alive at day 90; durations of invasive ventilation, ICU, and hospital admission; incidences of tracheostomy insertion and new kidney replacement therapy; and hospital discharge destination. RESULTS: A total of 3397 patients were included (median [IQR] age, 61 (48-71) years; 2157 [64%] male). The median (IQR) number of days free of the index hospital and alive at day 90 was 62 (0-77) days in the augmented protein group and 64 (0-77) days in the usual protein group, with an adjusted-for-period between-group median difference of -1.97 (95% CI, -7.24 to 3.30) days (P = .46). At day 90, a total of 1221 of 1681 patients (72.6%) were alive in the augmented protein group and 1269 of 1716 (74.0%) were alive in the usual protein group (risk ratio, 0.99 [95% CI, 0.95-1.03]). Between-group differences for secondary outcomes included the following: difference in median days free of hospital in survivors, 0.01 (95% CI, -1.94 to 1.96) days; difference in mean duration of invasive ventilation, 6.8 (95% CI, -3.0 to 16.5) hours; cause-specific hazard ratios for durations of ICU admission (time to live ICU discharge), 0.93 (95% CI, 0.88-1.00) and hospital admission (time to live hospital discharge), 0.96 (95% CI, 0.90-1.02); and risk ratio for tracheostomy, 1.15 (95% CI, 0.66-2.01) and new kidney replacement therapy, 0.97 (95% CI, 0.81-1.16). Discharge destinations were similar. CONCLUSIONS AND RELEVANCE: Augmenting enteral protein during critical illness did not improve number of days free of the index hospital and alive at day 90. TRIAL REGISTRATION: ANZCTR Identifier: ACTRN12621001484831.
引用
- Summers MJ, Chapple LS, Karahalios A, et al. Augmented Enteral Protein During Critical Illness: The TARGET Protein Randomized Clinical Trial. JAMA. 2025. PMID: 40495743. doi:10.1001/jama.2025.9110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。